PwPepwise

PT-141 / Bremelanotide

Sex & Libido

a.k.a. Vyleesi

MC4R / MC3R agonist

PT-141, also known as bremelanotide, is a synthetic peptide that works through the brain's melanocortin system to influence sexual desire and arousal.

§Dosing at a glance

3 protocols · from the research
What it's forDoseHow oftenHowFor how long
FDA-Approved Indication — Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women1.75 mgAs neededSubcutaneousInjected just under the skin, into the fat layer.52 wks
Male Erectile Dysfunction (Investigational — not FDA-approved for this indication)4–6 mg—SubcutaneousInjected just under the skin, into the fat layer.—
Weight Management (Investigational)2.5 mgTwice dailySubcutaneousInjected just under the skin, into the fat layer.15 days

Approximate values pulled from the research — double-check before dosing.

§01Summary

PT-141, also known as bremelanotide, is a synthetic peptide that works through the brain's melanocortin system to influence sexual desire and arousal. Unlike most other sexual health medications that act on blood vessels or hormones, bremelanotide targets receptors in the central nervous system to enhance the motivational and psychological components of sexual response. It received FDA approval in 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — a condition characterized by persistently low sexual desire accompanied by personal distress.

In two large, independent clinical trials, bremelanotide 1.75 mg administered as a subcutaneous injection on an as-needed basis significantly improves sexual desire scores and reduces distress related to low sexual desire compared to placebo1. These improvements are consistent across a broad range of patient ages, body weights, and hormone levels4. The drug has also been studied in men with erectile dysfunction, where it appears to support erectile function through a mechanism distinct from PDE5 inhibitors like sildenafil8,9, and early research suggests it may reduce caloric intake and body weight in obese individuals16. The most commonly reported side effects are nausea, flushing, and headache5.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Bremelanotide (PT-141) is a cyclic heptapeptide melanocortin receptor agonist derived from the naturally occurring alpha-melanocyte-stimulating hormone (α-MSH) and its synthetic analogue melanotan II. Its molecular structure incorporates a lactam bridge that confers metabolic stability relative to linear melanocortin peptides. Bremelanotide acts as an agonist at melanocortin receptor subtypes MC1R, MC3R, MC4R, and MC5R, with particular relevance of MC4R activity to its central neuromodulatory effects on sexual function and energy homeostasis2,8.

The primary mechanism underlying its pro-sexual effects is thought to involve MC3R and MC4R agonism within hypothalamic and limbic circuits, including the medial preoptic area, paraventricular nucleus, and mesolimbic dopaminergic pathways. Unlike PDE5 inhibitors (e.g., sildenafil), which act peripherally on vascular smooth muscle to enhance genital blood flow via the nitric oxide/cGMP cascade, bremelanotide acts centrally to modulate the motivational and appetitive components of sexual response — the subjective drive toward sexual activity rather than the hemodynamic mechanics of arousal8,9. This distinction is evidenced by its ability to produce significant erectile responses in healthy males even in the absence of visual sexual stimulation8,9, and by the observation that it improves subjective sexual desire and satisfaction in women without producing significant changes in objective vaginal vasocongestion18.

The complementarity of bremelanotide's central melanocortin mechanism with the peripheral PDE5 mechanism is demonstrated by the enhanced erectile response observed when subtherapeutic doses of both agents are co-administered19, suggesting additive or synergistic activity through independent pathways. MC4R's established role in hypothalamic regulation of energy balance and food intake also underlies bremelanotide's observed effects on caloric intake reduction and weight loss in obese subjects16, and forms the mechanistic rationale for its ongoing investigation in combination with the GLP-1/GIP dual agonist tirzepatide12.

Pharmacokineticaly, following intranasal administration, bremelanotide reaches peak plasma concentrations (Tmax) at approximately 0.50 hours with a mean half-life of 1.85–2.09 hours, exhibiting dose-proportional increases in Cmax and AUC8. The short half-life supports its on-demand dosing paradigm. At the approved subcutaneous route, clinically relevant hemodynamic effects — transient systolic and diastolic blood pressure increases of approximately 2.4–3.2 mmHg — are detectable by ambulatory blood pressure monitoring within the first 0–4 hours post-dose and are accompanied by compensatory heart rate reductions consistent with a baroreflex-mediated response rather than sympathomimetic activation3. No clinically significant pharmacokinetic drug–drug interactions were identified with ethanol11; however, plasma concentrations of indomethacin and naltrexone are reduced by bremelanotide co-administration through mechanisms not fully characterized in available summaries5.

§04Evidence & efficacy

Evidence base
193Studies
125Human
11Animal

Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women — FDA-Approved Indication:
Bremelanotide 1.75 mg SC significantly improves sexual desire as measured by the FSFI desire domain score compared to placebo (Study 301: +0.30, p<0.001; Study 302: +0.42, p<0.001; integrated analysis: +0.35, p<0.001) and significantly reduces distress related to low sexual desire on the FSDS-DAO item 13 (integrated: -0.33, p<0.001)1. Both co-primary endpoints were met in two independent, adequately-powered Phase 3 trials, providing robust and replicated evidence of efficacy1. These effects are consistent across subgroups defined by age, BMI, body weight, hormonal contraceptive use, presence of decreased arousal, and all four quartiles of baseline bioavailable testosterone4.

A Phase 2b dose-ranging trial confirmed statistically significant improvements at 1.25/1.75 mg pooled doses versus placebo across satisfying sexual events per month (+0.7 vs. +0.2, p=0.0180), FSFI total score (+3.6 vs. +1.9, p=0.0017), and FSDS-DAO total score (-11.1 vs. -6.8, p=0.0014)2. Sustained efficacy was observed over 52 weeks of open-label extension use, with no evidence of efficacy attrition over time15. A recent meta-analysis confirmed that bremelanotide improves both desire and arousal subscales of the FSFI as well as total FSFI score17.

Subjective Sexual Response in Women with Sexual Arousal Disorder:
Bremelanotide appears to improve subjective sexual desire (p=0.0114) and post-intercourse arousal satisfaction (p=0.0256) in women with sexual arousal disorder, though objective vaginal vasocongestion did not show statistically significant change in this study18.

Male Erectile Dysfunction:
Bremelanotide appears to support erectile function in men, including those who do not respond adequately to sildenafil. In sildenafil non-responders, subcutaneous doses of 4 mg and 6 mg produced statistically significant erectile responses9, and intranasal bremelanotide 10 mg produced a 33.5% positive clinical response rate versus 8.5% for placebo (p=0.03)7. Subtherapeutic doses of intranasal PT-141 combined with low-dose sildenafil appear to produce enhanced erectile responses compared to sildenafil alone19.

Weight Management:
Bremelanotide may reduce body weight and caloric intake in obese women, with statistically significant reductions in body weight (-1.3 kg over 16 days vs. placebo, p<0.0001) and mean caloric intake (~400–469 kcal/day reduction)16. A Phase 2 combination trial with tirzepatide for obesity is currently registered12.

Evidence Rating: Strong (for FDA-approved HSDD indication in premenopausal women); Preliminary (for male erectile dysfunction and weight management)

Rating Rationale: The Strong rating for HSDD is supported by two independent, adequately-powered Phase 3 RCTs both meeting co-primary endpoints with consistent effect sizes1, a confirmatory Phase 2b dose-finding trial2, replicated subgroup analyses4, long-term open-label extension data15, and meta-analytic confirmation17 — representing one of the most robust evidence bases for a peptide therapeutic in sexual medicine. The Preliminary rating for male ED reflects that while early RCTs show statistically significant effects in sildenafil non-responders7,9 and promising combination data exists19, these studies used earlier intranasal formulations at higher doses and have not been replicated at the FDA-approved subcutaneous dose or in large Phase 3 trials. The weight management signal is supported by two short-duration Phase 1 studies in obese women16 with ongoing Phase 2 investigation12, and requires larger and longer trials before efficacy conclusions can be drawn.

§05Safety

Bremelanotide has been evaluated in a comprehensive clinical development program spanning Phase 1 through Phase 3 trials and a 52-week open-label extension, providing a well-characterized safety profile at the FDA-approved dose of 1.75 mg subcutaneous.

Most Common Adverse Events (≥10% incidence at approved dose):
- Nausea: 40.0% (bremelanotide) vs. 1.3% (placebo)5
- Flushing: 20.3% vs. 1.3%5
- Headache: 11.3% vs. 1.9%5
- Injection site reactions: 5.4% vs. 0.5%5

Nausea was the primary reason for discontinuation in clinical trials5. No deaths occurred and serious adverse events were rare across the development program5.

Cardiovascular Effects:
Bremelanotide at 1.25 mg and 1.75 mg doses causes transient increases in ambulatory systolic and diastolic blood pressure of approximately 2.4–3.2 mmHg above placebo in the 0–4 hour post-dose window, accompanied by compensatory heart rate reductions of 4.6–4.7 bpm at the 1.75 mg dose3. Peak blood pressure increases typically resolve within 15 minutes3. Caution is warranted in patients with elevated cardiovascular risk5.

Hyperpigmentation:
Focal hyperpigmentation occurred in more than one-third of subjects receiving consecutive daily dosing but was rare with label-recommended as-needed dosing5. Adherence to prescribed dosing intervals is important.

Drug Interactions:
Clinically significant drug interactions were identified with indomethacin (reduced plasma concentrations) and naltrexone (reduced plasma concentrations)5. No clinically significant pharmacokinetic interaction was observed with ethanol co-administration11.

Long-Term Safety:
No new safety signals emerged over 52 weeks of open-label extension use15. The adverse event profile was consistent with that observed in the core double-blind phase.

§06History

PT-141 emerged from research into the melanocortin peptide system in the late 1990s, originally derived from melanotan II (MT-II), a synthetic cyclic analogue of α-melanocyte-stimulating hormone developed at the University of Arizona. While MT-II was initially investigated for tanning properties via MC1R agonism, researchers observed unexpected pro-erectile effects in preclinical and early human studies, redirecting interest toward sexual dysfunction applications. Palatin Technologies subsequently developed PT-141 — a structurally modified, metabolically stabilized cyclic heptapeptide — as a candidate for both male and female sexual dysfunction.

Early Phase 1/2 clinical trials in the mid-2000s established proof-of-concept for erectile function in men using intranasal delivery, demonstrating significant effects at doses above 7 mg intranasally, including in sildenafil non-responders8,9. A pivotal early study in women with sexual arousal disorder demonstrated improvements in subjective desire and arousal satisfaction18. These findings established the central melanocortin mechanism as a viable target for sexual dysfunction pharmacotherapy.

Development subsequently shifted focus to subcutaneous self-administration for premenopausal women with HSDD. Dose-finding Phase 2b trials identified the 1.75 mg subcutaneous dose as optimal2,10, leading to the pivotal RECONNECT Phase 3 program1. In June 2019, the FDA approved bremelanotide (branded Vyleesi) for acquired, generalized HSDD in premenopausal women — the first centrally-acting, on-demand pharmacotherapy for this indication1,2. Subsequent work has characterized its long-term safety5,15 and explored emerging indications including obesity management12,16, with the active research landscape continuing to expand.

§07References